ASCO conference reports from the Citeline team: updates from Allogene Therapeutics Inc., AstraZeneca PLC, Daiichi Sankyo Co., Ltd., Servier, Merck & Co., Inc., Bicara Therapeutics , Roche Holding AG, Elevation Oncology, Inc., and ImmunoGen, Inc.
Allogene has taken a step closer to developing a viable off-the-shelf CAR-T therapy, becoming the first to match the durability of established autologous